Glucose evaluation trial for remission (GETREM) in type 1 diabetes:: a European multicentre study

被引：27

作者：

Pozzilli, P ^{[1
]}

Manfrini, S ^{[1
]}

Buzzetti, R ^{[1
]}

Lampeter, E ^{[1
]}

De Leeuw, I ^{[1
]}

Iafusco, D ^{[1
]}

Prisco, M ^{[1
]}

Ionescu-Tirgoviste, C ^{[1
]}

Kolousková, S ^{[1
]}

Linn, T ^{[1
]}

Ludvigsson, J ^{[1
]}

Madàcsy, L ^{[1
]}

Seremak, A ^{[1
]}

Mrozikiewicz, AS ^{[1
]}

Mrozikiewicz, PM ^{[1
]}

Podar, T ^{[1
]}

Vavrinec, J ^{[1
]}

Vialettes, B ^{[1
]}

Visalli, N ^{[1
]}

Yilmaz, T ^{[1
]}

Browne, PD ^{[1
]}

机构：

[1] Univ Campus Biomedico, Dept Endocrinol & Diabet, I-00155 Rome, Italy

来源：

DIABETES RESEARCH AND CLINICAL PRACTICE | 2005年 / 68卷 / 03期

关键词：

type; 1; diabetes; remission; insulin; diabetes therapy; beta-cell destruction;

D O I：

10.1016/j.diabres.2004.10.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective: Strict metabolic control during the 1st year of type I diabetes is thought to be a key factor fur achieving clinical remission. The aims of this study were two-fold: (i) to evaluate the frequency and duration of spontaneous remission (defined according to the parameters issued by the International Diabetic Immunotherapy Group (IDIG)) in a European population of consecutive recent onset type I diabetes patients (aged 5-35 years), followed-up fur a period of 36 months with a common protocol of intensive insulin therapy and without adjunct immune-intervention; and (ii) to identify the predictive factors for clinical remission. Research design and method: A total of 189 consecutive patients with newly diagnosed type 1 diabetes according to ADA criteria were recruited in participating centres (Belgium, Czech Republic, Estonia, France, Germany, Hungary, Italy, Poland, Romania, Sweden and Turkey) and followed-up for a period of up to 36 months. In all patients, intensive insulin therapy was implemented consisting of three or four injections of regular insulin daily with NPH insulin at bedtime. Adjustment of insulin dose was made according to a common protocol. Various clinical characteristics (age, gender, severity of presentation, etc.), history (presence of diabetic siblings in the family, etc.) and integrated parameters of metabolic control (HbA(1c), blood glucose, the total insulin dose at hospital discharge adjusted for body weight) were collected. Results: Twenty-two patients (11.6%) experienced remission. The median duration of remission was 9.6 months and the range was 31 months. There was a wide variation among centres. Logistic regression analysis focused on the centre as the main variable in achieving remission. Conclusion: Remission was shown to be very heterogeneous between centres depending on 'other factors' such as patient care and family awareness of the disease rather than on 'measurable factors' such as sex, age, HbA(1c) and severity of presentation at diagnosis. Using intensive insulin therapy and optimisation of metabolic control, remission occurred in nearly one out of eight patients. (c) 2004 Elsevier Ireland Ltd. All rights reserved.

引用

页码：258 / 264

页数：7

共 33 条

[1]

ATKINSON MA, 1994, NEW ENGL J MED, V331, P1428

[2]

Bonfanti R, 1998, DIABETIC MED, V15, P844, DOI 10.1002/(SICI)1096-9136(199810)15:10<844::AID-DIA679>3.0.CO

[3]

2-A

[4] Oral insulin administration and residual β-cell function in recent-onset type 1 diabetes:: a multicentre randomised controlled trial [J].

Chaillous, L ;

Lefèvre, H ;

Thivolet, C ;

Boitard, C ;

Lahlou, N ;

Atlan-Gepner, C ;

Bouhanick, B ;

Mogenet, A ;

Nicolino, M ;

Carel, JC ;

Lecomte, P ;

Maréchaud, R ;

Bougnères, P ;

Charbonnel, B ;

Saï, P .

LANCET, 2000, 356 (9229) :545-549

[5] Analysis of 20 years of prospective registration of childhood onset diabetes - time trends and birth cohort effects [J].

Dahlquist, G ;

Mustonen, L .

ACTA PAEDIATRICA, 2000, 89 (10) :1231-1237

[6]

DCCT Res Grp, 1987, J CLIN ENDOCR METAB, V65, P30

[7]

DUPRE J, 1988, DIABETES CARE, V11, P37

[8]

Green A, 2000, LANCET, V355, P873

[9] Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes [J].

Greenbaum, CJ ;

Harrison, LC .

DIABETES, 2003, 52 (05) :1059-1065

[10] Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus [J].

Herold, KC ;

Hagopian, W ;

Auger, JA ;

Poumian-Ruiz, E ;

Taylor, L ;

Donaldson, D ;

Gitelman, SE ;

Harlan, DM ;

Xu, DL ;

Zivin, RA ;

Bluestone, JA .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (22) :1692-1698

← 1 2 3 4 →